Hepatitis C virus protease inhibitor and NS5A inhibitor combination

This page covers all Hepatitis C virus protease inhibitor and NS5A inhibitor combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HCV NS3/4A protease and NS5A protein, HCV NS3/4A protease; HCV NS5A protein.

Targets

HCV NS3/4A protease and NS5A protein · HCV NS3/4A protease; HCV NS5A protein

Phase 3 pipeline (2)

• ABT-450/r/ABT-267 · AbbVie · Virology/Hepatology
  ABT-450/r/ABT-267 is a fixed-dose combination of a hepatitis C virus NS3/4A protease inhibitor (ABT-450) boosted with ritonavir and an NS5A inhibitor (ABT-267) that blocks viral replication.
• Paritaprevir/ritonavir/ombitasvir · AbbVie · Virology/Hepatology
  Paritaprevir inhibits hepatitis C virus NS3/4A protease, while ritonavir boosts its levels, and ombitasvir inhibits the NS5A protein, together blocking viral replication.